Clinical trials: latest news

Clinical trials resources

  • Clinical trials

    A clinical trial is a study in which a new treatment is assessed.There are legal requirements on how a trial should be run.If you choose to join a...

    From: Factsheets

    Information level Level 2
  • Thinking about joining a clinical trial?

    Before you make a decision about joining a clinical trial, make sure you fully understand what’s involved.There will be benefits and risks to joining any clinical trial.Discuss...

    From: Factsheets

    Information level Level 2

Clinical trials features

Clinical trials in your own words

Clinical trials news from aidsmap

More news

Clinical trials news selected from other sources

  • We Love the Jargon, We Hate the Jargon!

    This blog post by Angelo Kaggwa-Katumba and Kay Marshall talks about the essential work of connecting journalists and researchers and how advocates are the linchpin.

    20 July 2018 | AVAC
  • Superior AIDS-Kaposi’s Sarcoma Treatment Identified

    A clinical trial funded by the National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute comparing three chemotherapy regimens in combination with antiretroviral treatment (ART) for treatment of advanced AIDS-Kaposi’s sarcoma patients in Africa and South America has ended early. Interim data showed that participants who were treated with paclitaxel plus ART had better tumor outcomes than participants who received the other treatment regimens.

    27 June 2018 | National Institute of Allergies and Infectious Diseases (NIAID)
  • NHS England considers expanding PrEP trial - NAT comment

    Deborah Gold, Chief Executive of NAT (National AIDS Trust) said: “This proposed trial expansion, from 10,000 to 13,000 participants, is essential and we urge NHS England to confirm the decision urgently. This expansion was first proposed by NAT as necessary to estimate accurately the likely long-term needs of a routinely commissioned PrEP programme and it’s great news that this is now on the table.

    18 June 2018 | National AIDS Trust
  • My PrEP story: Patrick (part 2)

    In his second My PrEP Story blog Dr. Patrick Baxter talks about being on Gilead’s DISCOVER Trial. What’s the trial attempting to do? And why the lack of community consultation? And is he really using PrEP?

    10 April 2018 | Prepster
  • Gay men seeking HIV-preventing PrEP drugs are being ‘turned away’ from sexual health clinics over trial capacity

    More than two dozen sexual health clinics in England are now turning away gay men who are seeking to take HIV-preventing drugs, PinkNews has found.

    21 March 2018 | Pink News
  • Longstanding Mombasa Cohort helps answer questions about HIV risk and transmission

    This month, Fred Hutchinson Cancer Research Center virologist Dr. Julie Overbaugh and her collaborators in Kenya and the U.S. celebrated the 25th anniversary of a unique group of HIV research participants — high-risk women in Mombasa, Kenya — who helped change the landscape of HIV transmission research.

    28 February 2018 | Fred Hutch
  • An Exciting Act II for the Study That Proved Treating HIV Early Is Best

    With a grant to follow their large study population through 2021, researchers hope to gain vital new insights about HIV infection.

    25 February 2018 | Poz
  • NIH study supports use of short-term HIV treatment interruption in clinical trials

    A short-term pause in HIV treatment during a carefully monitored clinical trial does not lead to lasting expansion of the HIV reservoir nor cause irreversible damage to the immune system, new findings suggest.

    11 January 2018 | National Institutes of Health
  • Setting the Standard: New prevention trials in the era of oral PrEP

    There’s a lot going on in the world of HIV prevention research right now. One key issue is how participants might access oral PrEP as part of HIV prevention trials. It may seem simple: trial participants have the right to the highest standard of HIV prevention and care as part of participation. But the ethics, trial design issues and the mechanisms by which interventions are provided as standard of care are quite complex. Opinions differ and politics abound.

    08 December 2017 | AVAC
  • For cancer patients with HIV, immunotherapy appears safe

    Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials

    08 November 2017 | Fred Hutch
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.